Your browser doesn't support javascript.
loading
Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
Anthonet L. Koen; Alane Izu; Vicky Baillie; Gaurav Kwatra; Clare L. Cutland; Lee Fairlie; Sherman D. Padayachee; Keertan Dheda; Shaun L. Barnabas; Qasim Ebrahim Bhorat; Carmen Briner; Katija Ahmed; Sutika Bhikha; Jinal N. Bhiman; Jeanine du Plessis; Aliasgar Esmail; Elizea Horne; Shi-Hsia Hwa; Aylin Oomen-Jose; Teresa Lambe; Matt Laubscher; Mookho Malahleha; Gabriella Benade; Shakeel McKenzie; Suzette Oelofse; Faeezah Patel; Sureshnee Pillay; Sarah Rhead; Hylton Rodel; Carol Taoushanis; Houriiyah Tegally; Asha Thombrayil; Tonya Villafana; Sarah Gilbert; Andrew J. Pollard; Shabir Madhi.
Afiliación
  • Anthonet L. Koen; University of the Witwatersrand
  • Alane Izu; University of the Witwatersrand
  • Vicky Baillie; University of the Witwatersrand
  • Gaurav Kwatra; University of the Witwatersrand
  • Clare L. Cutland; University of the Witwatersrand
  • Lee Fairlie; University of the Witwatersrand
  • Sherman D. Padayachee; Setshaba Research Centre
  • Keertan Dheda; University of Cape Town Lung Institute
  • Shaun L. Barnabas; Family Centre for Research with Ubuntu, Department of Paediatrics, Stellenbosch University
  • Qasim Ebrahim Bhorat; Soweto Clinical Trials Centre, Soweto, South Africa
  • Carmen Briner; University of the Witwatersrand
  • Katija Ahmed; Setshaba Research Centre
  • Sutika Bhikha; University of the Witwatersrand
  • Jinal N. Bhiman; National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Jeanine du Plessis; University of the Witwatersrand
  • Aliasgar Esmail; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute
  • Elizea Horne; University of the Witwatersrand
  • Shi-Hsia Hwa; Africa Health Research Institute
  • Aylin Oomen-Jose; University of the Witwatersrand
  • Teresa Lambe; Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Matt Laubscher; University of the Witwatersrand
  • Mookho Malahleha; Setshaba Research Centre
  • Gabriella Benade; University of the Witwatersrand
  • Shakeel McKenzie; University of the Witwatersrand
  • Suzette Oelofse; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute
  • Faeezah Patel; University of the Witwatersrand
  • Sureshnee Pillay; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal
  • Sarah Rhead; Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Hylton Rodel; Africa Health Research Institute
  • Carol Taoushanis; University of the Witwatersrand
  • Houriiyah Tegally; Stellenbosch University
  • Asha Thombrayil; University of the Witwatersrand
  • Tonya Villafana; AstraZeneca
  • Sarah Gilbert; Nuffield Department of Medicine, University of Oxford
  • Andrew J. Pollard; Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Shabir Madhi; University of the Witwatersrand
Preprint en Inglés | medRxiv | ID: ppmedrxiv-22277743
ABSTRACT
In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection 90.6% against wild-type and 77.1% against the Delta variant [≥]9 months after vaccination. VE against infection with the Beta variant, which preceded circulation of Delta, was 6.7%. Clinical trial identifierCT.gov NCT04444674
Licencia
cc_by_nc_nd
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Estudio pronóstico / Rct Idioma: Inglés Año: 2022 Tipo del documento: Preprint
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Estudio pronóstico / Rct Idioma: Inglés Año: 2022 Tipo del documento: Preprint
...